BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715-1726. [PMID: 25037630 DOI: 10.1182/blood-2014-02-558296] [Cited by in Crossref: 189] [Cited by in F6Publishing: 171] [Article Influence: 23.6] [Reference Citation Analysis]
Number Citing Articles
1 Prohászka Z, Kirschfink M, Frazer-Abel A. Complement analysis in the era of targeted therapeutics. Mol Immunol 2018;102:84-8. [PMID: 29933889 DOI: 10.1016/j.molimm.2018.06.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
2 Gavriatopoulou M, Terpos E, Kastritis E, Dimopoulos MA. Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia. Expert Opinion on Investigational Drugs 2016;26:197-205. [DOI: 10.1080/13543784.2017.1275561] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
3 Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 2018;33:635-45. [PMID: 29106598 DOI: 10.1093/ndt/gfx196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
4 Javaux C, Stordeur P, Azarkan M, Mascart F, Baeyens-volant D. Isolation of a thiol-dependent serine protease in peanut and investigation of its role in the complement and the allergic reaction. Molecular Immunology 2016;75:133-43. [DOI: 10.1016/j.molimm.2016.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ozen A, Kasap N, Vujkovic-Cvijin I, Apps R, Cheung F, Karakoc-Aydiner E, Akkelle B, Sari S, Tutar E, Ozcay F, Uygun DK, Islek A, Akgun G, Selcuk M, Sezer OB, Zhang Y, Kutluk G, Topal E, Sayar E, Celikel C, Houwen RHJ, Bingol A, Ogulur I, Eltan SB, Snow AL, Lake C, Fantoni G, Alba C, Sellers B, Chauvin SD, Dalgard CL, Harari O, Ni YG, Wang MD, Devalaraja-Narashimha K, Subramanian P, Ergelen R, Artan R, Guner SN, Dalgic B, Tsang J, Belkaid Y, Ertem D, Baris S, Lenardo MJ. Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease. Nat Immunol 2021;22:128-39. [PMID: 33398182 DOI: 10.1038/s41590-020-00830-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Timmermans SA, van Paassen P. The Authors Reply. Kidney International 2017;92:267-8. [DOI: 10.1016/j.kint.2017.03.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Noris M, Remuzzi G. Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both? Kidney Int 2019;96:13-5. [PMID: 31229026 DOI: 10.1016/j.kint.2019.02.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Timmermans SAMEG, Damoiseaux JGMC, Werion A, Reutelingsperger CP, Morelle J, van Paassen P. Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes. Kidney Int Rep 2021;6:1099-109. [PMID: 33912760 DOI: 10.1016/j.ekir.2021.01.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Fakhouri F, Frémeaux-Bacchi V. Monitoring Complement Activation: The New Conundrum in Thrombotic Microangiopathies. Clin J Am Soc Nephrol 2019;14:1682-3. [PMID: 31811084 DOI: 10.2215/CJN.12111019] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, Amer H, Hogan WJ, Marshall AL, Sethi S, Tran CL, Chen D, Pruthi RK, Ashrani AA, Fervenza FC, Cramer CH 2nd, Rodriguez V, Wolanskyj AP, Thomé SD, Hook CC; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc 2016;91:1189-211. [PMID: 27497856 DOI: 10.1016/j.mayocp.2016.05.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
11 Fontana F, Alfano G, Bardhushi E, Ligabue G, Giovanella S, Neri I, Cappelli G. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report. Am J Case Rep 2019;20:1460-5. [PMID: 31582717 DOI: 10.12659/AJCR.916994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr Nephrol 2019;34:943-9. [PMID: 30693384 DOI: 10.1007/s00467-019-4192-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
13 Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provôt F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Châtelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Frémeaux-Bacchi V. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 2021;137:2438-49. [PMID: 33270832 DOI: 10.1182/blood.2020009280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
14 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]
15 Meroni PL, Macor P, Durigutto P, De Maso L, Gerosa M, Ferraresso M, Borghi MO, Mollnes TE, Tedesco F. Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood 2016;127:365-7. [DOI: 10.1182/blood-2015-09-672139] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
16 Rotz SJ, Luebbering N, Dixon BP, Gavriilaki E, Brodsky RA, Dandoy CE, Jodele S, Davies SM. In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy. Blood Adv 2017;1:1632-4. [PMID: 29296809 DOI: 10.1182/bloodadvances.2017008250] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
17 Liszewski MK, Atkinson JP. Complement regulators in human disease: lessons from modern genetics. J Intern Med 2015;277:294-305. [PMID: 25495259 DOI: 10.1111/joim.12338] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
18 Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2016;109:27-33. [PMID: 25899302 DOI: 10.1093/qjmed/hcv082] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
19 Rand JH, Wu XX, Wolgast LR, Lei V, Conway EM. A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. Thromb Res 2017;156:119-25. [PMID: 28628799 DOI: 10.1016/j.thromres.2017.06.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
20 Cugno M, Tedeschi S, Ardissino G. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment. J Thromb Haemost 2015;13:485-6. [PMID: 25345369 DOI: 10.1111/jth.12764] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
21 Blasco M, Guillén E, Quintana LF, Garcia-Herrera A, Piñeiro G, Poch E, Carreras E, Campistol JM, Diaz-Ricart M, Palomo M. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J 2021;14:1055-66. [PMID: 33841853 DOI: 10.1093/ckj/sfaa195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Coppo R, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, Salizzoni M, Galbusera M, Gotti E, Daina E, Noris M, Remuzzi G. Liver transplantation for aHUS: still needed in the eculizumab era? Pediatr Nephrol. 2016;31:759-768. [PMID: 26604087 DOI: 10.1007/s00467-015-3278-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
23 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
24 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019;34:2261-77. [PMID: 30402748 DOI: 10.1007/s00467-018-4091-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
25 Kuppachi S, Smith RJH, Thomas CP. Evaluation of Genetic Renal Diseases in Potential Living Kidney Donors. Curr Transpl Rep 2015;2:1-14. [DOI: 10.1007/s40472-014-0042-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
26 Kaartinen K, Safa A, Kotha S, Ratti G, Meri S. Complement dysregulation in glomerulonephritis. Semin Immunol 2019;45:101331. [PMID: 31711769 DOI: 10.1016/j.smim.2019.101331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
27 Riedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, Walden U, Maier T, Heininger D, Jeller V, Weiss G, van den Heuvel L, Zimmerhackl LB, Würzner R, Jungraithmayr TC. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods 2016;435:60-7. [PMID: 27238216 DOI: 10.1016/j.jim.2016.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Åkesson A, Zetterberg E, Klintman J. At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature: At the Cross Section of TMA and aHUS. Ther Apher Dial 2017;21:304-19. [DOI: 10.1111/1744-9987.12535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
29 Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-bacchi V. The rational use of complement inhibitors in kidney diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.021] [Reference Citation Analysis]
30 Urban A, Kowalska D, Stasiłojć G, Kuźniewska A, Skrobińska A, Arjona E, Alonso EC, Fenollosa Segarra MÁ, Jongerius I, Spaapen R, Satchell S, Thiel M, Ołdziej S, Rodriguez de Córdoba S, Okrój M. Gain-of-Function Mutations R249C and S250C in Complement C2 Protein Increase C3 Deposition in the Presence of C-Reactive Protein. Front Immunol 2021;12:724361. [PMID: 34899688 DOI: 10.3389/fimmu.2021.724361] [Reference Citation Analysis]
31 Meuleman MS, Fremeaux-Bacchi V, Roumenina LT, Chauvet S. Ex Vivo Complement Activation on Endothelial Cells: Research and Translational Value. Trends Mol Med 2021;27:418-21. [PMID: 33648869 DOI: 10.1016/j.molmed.2021.01.008] [Reference Citation Analysis]
32 Frazer-Abel A, Kirschfink M, Prohászka Z. Expanding Horizons in Complement Analysis and Quality Control. Front Immunol 2021;12:697313. [PMID: 34434189 DOI: 10.3389/fimmu.2021.697313] [Reference Citation Analysis]
33 Zuckerman JE, Chang A. Complement and Renal Thrombotic Microangiopathy Associated With Hypertension and Scleroderma. Adv Chronic Kidney Dis 2020;27:149-54. [PMID: 32553247 DOI: 10.1053/j.ackd.2019.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, Heyne N. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10:310-319. [PMID: 28621343 DOI: 10.1093/ckj/sfw115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
35 Williams LA, Marques MB; for the Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). Am J Clin Pathol 2016;145:158-65. [DOI: 10.1093/ajcp/aqv086] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
36 Noris M, Remuzzi G. Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule? Kidney Int 2020;98:1084-7. [PMID: 33126970 DOI: 10.1016/j.kint.2020.06.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Portuguese AJ, Gleber C, Passero FC, Lipe B. A review of thrombotic microangiopathies in multiple myeloma. Leukemia Research 2019;85:106195. [DOI: 10.1016/j.leukres.2019.106195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A. Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Front Immunol 2019;10:1282. [PMID: 31231391 DOI: 10.3389/fimmu.2019.01282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
39 Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol 2019;15:87-108. [PMID: 30607032 DOI: 10.1038/s41581-018-0098-z] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 34.7] [Reference Citation Analysis]
40 Békássy ZD, Kristoffersson A, Rebetz J, Tati R, Olin AI, Karpman D. Aliskiren inhibits renin-mediated complement activation. Kidney International 2018;94:689-700. [DOI: 10.1016/j.kint.2018.04.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
41 Gatault P, Brachet G, Ternant D, Degenne D, Récipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. MAbs 2015;7:1205-11. [PMID: 26337866 DOI: 10.1080/19420862.2015.1086049] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
42 Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016;2016:217-25. [PMID: 27913483 DOI: 10.1182/asheducation-2016.1.217] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
43 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
44 Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol 2017;12:50-9. [PMID: 27799617 DOI: 10.2215/CJN.06440616] [Cited by in Crossref: 94] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
45 May O, Merle NS, Grunenwald A, Gnemmi V, Leon J, Payet C, Robe-Rybkine T, Paule R, Delguste F, Satchell SC, Mathieson PW, Hazzan M, Boulanger E, Dimitrov JD, Fremeaux-Bacchi V, Frimat M, Roumenina LT. Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. Front Immunol 2018;9:3008. [PMID: 30619356 DOI: 10.3389/fimmu.2018.03008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
46 Han SS, Yu XJ, Wang SX, Zhou FD, Yu F, Zhao MH. A novel mutation in complement 2 accompanied by susceptibility variants in C3 glomerulonephritis: A case study. Nefrologia (Engl Ed) 2019;39:664-71. [PMID: 31014550 DOI: 10.1016/j.nefro.2019.01.008] [Reference Citation Analysis]
47 Emirova K, Volokhina E, Tolstova E, van den Heuvel B. Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab. BMJ Case Rep 2016;2016:bcr2015213928. [PMID: 26880823 DOI: 10.1136/bcr-2015-213928] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
48 Frazer-abel A, Sepiashvili L, Mbughuni M, Willrich M. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Elsevier; 2016. pp. 1-75. [DOI: 10.1016/bs.acc.2016.06.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
49 Oliveira DS, Lima TG, Benevides FLN, Barbosa SAT, Oliveira MA, Boris NP, Silva HF. Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country. Hematol Transfus Cell Ther 2019;41:119-24. [PMID: 31079658 DOI: 10.1016/j.htct.2018.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
50 Rawish E, Sauter M, Sauter R, Nording H, Langer HF. Complement, inflammation and thrombosis. Br J Pharmacol 2021;178:2892-904. [PMID: 33817781 DOI: 10.1111/bph.15476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Pecoraro C, Ferretti AV, Rurali E, Galbusera M, Noris M, Remuzzi G. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. Am J Kidney Dis 2015;66:1067-70. [PMID: 26409664 DOI: 10.1053/j.ajkd.2015.06.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
52 Santiesteban-Lores LE, Carneiro MC, Isaac L, Bavia L. Complement System in Alcohol-Associated Liver Disease. Immunol Lett 2021;236:37-50. [PMID: 34111475 DOI: 10.1016/j.imlet.2021.05.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;3:CD012862. [PMID: 33783815 DOI: 10.1002/14651858.CD012862.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, Yuan X, Sperati CJ, Moliterno AR, Brodsky RA. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv 2021;5:1504-12. [PMID: 33683339 DOI: 10.1182/bloodadvances.2020003175] [Reference Citation Analysis]
55 Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020;98:314-322. [PMID: 32461141 DOI: 10.1016/j.kint.2020.05.013] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 58.0] [Reference Citation Analysis]
56 Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One 2021;16:e0261113. [PMID: 34928990 DOI: 10.1371/journal.pone.0261113] [Reference Citation Analysis]
57 Artinger K, Hackl G, Schilcher G, Eisner F, Pollheimer MJ, Mache C, Weiss EC, Eller K, Eller P. The conundrum of postpartum thrombotic Microangiopathy: case report and considerations for management. BMC Nephrol 2019;20:91. [PMID: 30871486 DOI: 10.1186/s12882-019-1286-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Taylor RP, Lindorfer MA. Mechanisms of Complement-Mediated Damage in Hematological Disorders. Semin Hematol 2018;55:118-23. [PMID: 30032747 DOI: 10.1053/j.seminhematol.2018.02.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
59 Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, van den Heuvel LP, Mollnes TE. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clinical Immunology 2015;160:237-43. [DOI: 10.1016/j.clim.2015.05.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
60 Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015;125:3253-62. [PMID: 25833956 DOI: 10.1182/blood-2014-09-600411] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 15.6] [Reference Citation Analysis]
61 Hyvärinen S, Meri S, Jokiranta TS. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood 2016;127:2701-10. [PMID: 27006390 DOI: 10.1182/blood-2015-11-680009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
62 Timmermans SAMEG, Abdul-Hamid MA, Potjewijd J, Theunissen ROMFIH, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension. J Am Soc Nephrol 2018;29:2234-43. [PMID: 29858281 DOI: 10.1681/ASN.2018020184] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 8.8] [Reference Citation Analysis]
63 Freist M, Garrouste C, Szlavik N, Coppo P, Lautrette A, Heng AE. Efficacy of eculizumab in an adult patient with HIV-associated hemolytic uremic syndrome: A case report. Medicine (Baltimore) 2017;96:e9358. [PMID: 29390523 DOI: 10.1097/MD.0000000000009358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Dhakal P, Bhatt VR. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? Bone Marrow Transplant 2017;52:352-6. [PMID: 27775697 DOI: 10.1038/bmt.2016.253] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
65 Hallstensen RF, Bergseth G, Foss S, Jæger S, Gedde-dahl T, Holt J, Christiansen D, Lau C, Brekke O, Armstrong E, Stefanovic V, Andersen JT, Sandlie I, Mollnes TE. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 2015;220:452-9. [DOI: 10.1016/j.imbio.2014.11.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
66 Yamada Y, Abe R, Okano Y, Miyakawa Y. Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome. Intern Med 2017;56:1085-8. [PMID: 28458317 DOI: 10.2169/internalmedicine.56.7862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
67 Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort: Eculizumab treatment of aHUS in Australia. Intern Med J 2015;45:1054-65. [DOI: 10.1111/imj.12864] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
68 Bettoni S, Galbusera M, Gastoldi S, Donadelli R, Tentori C, Spartà G, Bresin E, Mele C, Alberti M, Tortajada A, Yebenes H, Remuzzi G, Noris M. Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. J Immunol 2017;199:1021-40. [PMID: 28652401 DOI: 10.4049/jimmunol.1601121] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
69 Bacchetta J, Cochat P. Primary disease recurrence—effects on paediatric renal transplantation outcomes. Nat Rev Nephrol 2015;11:371-84. [PMID: 25917555 DOI: 10.1038/nrneph.2015.54] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
70 Bouwmeester RN, van de Kar NCAJ, Wetzels JFM. Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome. Kidney Int 2021;100:265-8. [PMID: 33675845 DOI: 10.1016/j.kint.2021.02.033] [Reference Citation Analysis]
71 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
72 Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol 2021. [PMID: 34912108 DOI: 10.1038/s41577-021-00665-1] [Reference Citation Analysis]
73 Tsai HHC, Moyers JT, Moore CJ, Thinn M. Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab. Am J Case Rep 2021;22:e929616. [PMID: 33678802 DOI: 10.12659/AJCR.929616] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Syed S, Hakala P, Singh AK, Lapatto HAK, King SJ, Meri S, Jokiranta TS, Haapasalo K. Role of Pneumococcal NanA Neuraminidase Activity in Peripheral Blood. Front Cell Infect Microbiol 2019;9:218. [PMID: 31297339 DOI: 10.3389/fcimb.2019.00218] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
75 Li J, Liu B. The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy. Cytokine Growth Factor Rev 2021;58:75-81. [PMID: 33558131 DOI: 10.1016/j.cytogfr.2020.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA. Modified Ham test for atypical hemolytic uremic syndrome. Blood 2015;125:3637-46. [PMID: 25862562 DOI: 10.1182/blood-2015-02-629683] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
77 Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2018;65:509-25. [DOI: 10.1016/j.pcl.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
78 Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015;14:857-77. [PMID: 26493766 DOI: 10.1038/nrd4657] [Cited by in Crossref: 227] [Cited by in F6Publishing: 210] [Article Influence: 32.4] [Reference Citation Analysis]
79 Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1-13. [PMID: 32299776 DOI: 10.1016/j.trsl.2020.04.007] [Cited by in Crossref: 979] [Cited by in F6Publishing: 911] [Article Influence: 489.5] [Reference Citation Analysis]
80 Percheron L, Gramada R, Tellier S, Salomon R, Harambat J, Llanas B, Fila M, Allain-launay E, Lapeyraque A, Leroy V, Adra A, Bérard E, Bourdat-michel G, Chehade H, Eckart P, Merieau E, Piètrement C, Sellier-leclerc A, Frémeaux-bacchi V, Dimeglio C, Garnier A. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 2018;33:1385-94. [DOI: 10.1007/s00467-018-3903-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
81 Riedl M, Noone DG, Khan MA, Pluthero FG, Kahr WHA, Palaniyar N, Licht C. Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells. Kidney Int Rep 2017;2:66-75. [PMID: 29142942 DOI: 10.1016/j.ekir.2016.08.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
82 Vidal E, Garzotto F, Parolin M, Manenti C, Zanin A, Bellettato M, Remuzzi G, Goldstein SL, Murer L, Ronco C. Therapeutic Plasma Exchange in Neonates and Infants: Successful Use of a Miniaturized Machine. Blood Purif 2017;44:100-5. [DOI: 10.1159/000470827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
83 Thurman JM, Nester CM. All Things Complement. Clin J Am Soc Nephrol 2016;11:1856-66. [PMID: 27340286 DOI: 10.2215/CJN.01710216] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
84 Schoettler M, Lehmann L, Li A, Ma C, Duncan C. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors. Biol Blood Marrow Transplant 2019;25:e163-8. [PMID: 30639820 DOI: 10.1016/j.bbmt.2018.12.840] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
85 Thomson N, Ulrickson M. Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature. Clin Case Rep 2016;4:773-6. [PMID: 27525082 DOI: 10.1002/ccr3.628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
86 Timmermans SAMEG, Werion A, Spaanderman MEA, Reutelingsperger CP, Damoiseaux JGMC, Morelle J, van Paassen P. The natural course of pregnancies in women with primary atypical haemolytic uraemic syndrome and asymptomatic relatives. Br J Haematol 2020;190:442-9. [PMID: 32342491 DOI: 10.1111/bjh.16626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Passot C, Sberro-Soussan R, Bertrand D, Caillard S, Schvartz B, Domenger C, Contin-Bordes C, Paintaud G, Halimi JM, Ternant D, Gatault P. Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. Br J Clin Pharmacol 2021;87:2236-46. [PMID: 33118186 DOI: 10.1111/bcp.14627] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Benamu E. Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infect Dis Clin North Am 2020;34:271-310. [PMID: 32444011 DOI: 10.1016/j.idc.2020.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Le Clech A, Simon-tillaux N, Provôt F, Delmas Y, Vieira-martins P, Limou S, Halimi J, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-chiche N, Rondeau E, Frémeaux-bacchi V, Fakhouri F. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney International 2019;95:1443-52. [DOI: 10.1016/j.kint.2019.01.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
90 Ghias MH, Hyde MJ, Tomalin LE, Morgan BP, Alavi A, Lowes MA, Piguet V. Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. J Invest Dermatol 2020;140:531-536.e1. [PMID: 31870626 DOI: 10.1016/j.jid.2019.09.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
91 Bohl SR, Kuchenbauer F, von Harsdorf S, Kloevekorn N, Schönsteiner SS, Rouhi A, Schwarzwälder P, Döhner H, Bunjes D, Bommer M. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy. Biol Blood Marrow Transplant 2017;23:2172-7. [PMID: 28860002 DOI: 10.1016/j.bbmt.2017.08.019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
92 Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Front Immunol 2019;10:853. [PMID: 31118930 DOI: 10.3389/fimmu.2019.00853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
93 Boudhabhay I, Grunenwald A, Roumenina LT. Complement C3 Deposition on Endothelial Cells Revealed by Flow Cytometry. In: Roumenina LT, editor. The Complement System. New York: Springer US; 2021. pp. 97-105. [DOI: 10.1007/978-1-0716-1016-9_9] [Reference Citation Analysis]
94 Blasco M, Martínez-Roca A, Rodríguez-Lobato LG, Garcia-Herrera A, Rosiñol L, Castro P, Fernández S, Quintana LF, Cibeira MT, Bladé J, Fernández de Larrea C, Tovar N, Jimenez R, Poch E, Guillen E, Campistol JM, Carreras E, Diaz-Ricart M, Palomo M. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol 2021;193:181-7. [PMID: 32469083 DOI: 10.1111/bjh.16796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
95 Bernards J, Doubel P, Meeus G, Lerut E, Corveleyn A, Van Den Heuvel LP, Meersseman W, Kuypers DK, Claes KJ. Hyperhomocysteinemia: a trigger for complement-mediated TMA? Acta Clin Belg 2021;76:65-9. [PMID: 31401947 DOI: 10.1080/17843286.2019.1649039] [Reference Citation Analysis]
96 Grunenwald A, Roumenina LT. The Benefits of Complement Measurements for the Clinical Practice. Methods Mol Biol 2021;2227:1-20. [PMID: 33847926 DOI: 10.1007/978-1-0716-1016-9_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 McDonald CR, Tran V, Kain KC. Complement Activation in Placental Malaria. Front Microbiol 2015;6:1460. [PMID: 26733992 DOI: 10.3389/fmicb.2015.01460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
98 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
99 Yuan X, Yu J, Gerber G, Chaturvedi S, Cole M, Chen H, Metjian A, Sperati CJ, Braunstein EM, Brodsky RA. Ex vivo assays to detect complement activation in complementopathies. Clin Immunol 2020;221:108616. [PMID: 33148511 DOI: 10.1016/j.clim.2020.108616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Lammerts RGM, Lagendijk LM, Tiller G, Dam WA, Lancaster HL, Daha MR, Seelen MA, Hepkema BG, Pol RA, Leuvenink HGD, Molema G, van den Born J, Berger SP. Machine-perfused donor kidneys as a source of human renal endothelial cells. Am J Physiol Renal Physiol 2021;320:F947-62. [PMID: 33719571 DOI: 10.1152/ajprenal.00541.2020] [Reference Citation Analysis]
101 Sicre de Fontbrune F, Peffault de Latour R. Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology 2018;55:124-9. [DOI: 10.1053/j.seminhematol.2018.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
102 Kawano N, Abe T, Ikeda N, Nagahiro Y, Kawano S, Tochigi T, Nakaike T, Yamashita K, Kubo K, Yamanaka A, Terasaka S, Marutsuka K, Mashiba K, Kikuchi I, Shimoda K, Matsumoto M, Ochiai H. Clinical features and outcomes of four atypical hemolytic uremic syndrome cases at a single institution in Miyazaki Prefecture from 2015 to 2019. Ren Replace Ther 2022;8. [DOI: 10.1186/s41100-022-00396-6] [Reference Citation Analysis]
103 Noris M, Remuzzi G. Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. Seminars in Nephrology 2017;37:447-63. [DOI: 10.1016/j.semnephrol.2017.05.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
104 Timmermans SAMEG, van Paassen P. The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. J Clin Med 2021;10:3034. [PMID: 34300201 DOI: 10.3390/jcm10143034] [Reference Citation Analysis]
105 Abbas F, El Kossi M, Kim JJ, Shaheen IS, Sharma A, Halawa A. Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases. World J Transplantation 2018; 8(6): 203-219 [PMID: 30370231 DOI: 10.5500/wjt.v8.i6.203] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
106 Sadler JE. Atypical HUS may become a diagnosis of inclusion. Blood 2015;125:3525-6. [PMID: 26045594 DOI: 10.1182/blood-2015-04-640656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
107 Passot C, Desvignes C, Ternant D, Bejan-angoulvant T, Duveau A, Gatault P, Paintaud G. Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. Bioanalysis 2017;9:1227-35. [DOI: 10.4155/bio-2017-0070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
108 Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M. Complement Activation and Thrombotic Microangiopathies. Clin J Am Soc Nephrol 2019;14:1719-32. [PMID: 31694864 DOI: 10.2215/CJN.05830519] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 7.3] [Reference Citation Analysis]
109 Badiola J, Navarrete-Navarrete N, Sabio JM. Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review. Rheumatol Int 2019;39:359-65. [PMID: 30554307 DOI: 10.1007/s00296-018-4228-5] [Reference Citation Analysis]
110 Bu F, Meyer NC, Zhang Y, Borsa NG, Thomas C, Nester C, Smith RJ. Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am J Kidney Dis 2015;65:968-9. [PMID: 25818678 DOI: 10.1053/j.ajkd.2015.02.326] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
111 Angioi A, Fervenza FC, Sethi S, Zhang Y, Smith RJ, Murray D, Van Praet J, Pani A, De Vriese AS. Diagnosis of complement alternative pathway disorders. Kidney International 2016;89:278-88. [DOI: 10.1016/j.kint.2015.12.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
112 Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology 2016;71:131-42. [DOI: 10.1016/j.molimm.2016.01.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
113 Webb TN, Griffiths H, Miyashita Y, Bhatt R, Jaffe R, Moritz M, Hofer J, Swiatecka-Urban A. Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab. Int J Med Pharm Case Reports 2015;4:105-12. [PMID: 27135055 DOI: 10.9734/IJMPCR/2015/18771] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
114 Duineveld C, Wetzels JFM. Complement inhibitors are not useful in secondary hemolytic uremic syndromes. Kidney Int 2019;96:829-33. [PMID: 31543154 DOI: 10.1016/j.kint.2019.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
115 Gentile M, Rossi GM, Delsante M, Zambrano C, Maria AD, Fiaccadori E, Manenti L. Atypical hemolytic uremic syndrome complicating relapsing cryoglobulinemic membranoproliferative glomerulonephritis despite hepatitis C eradication. J Nephrol 2021. [PMID: 33730342 DOI: 10.1007/s40620-021-00998-z] [Reference Citation Analysis]
116 Roumenina LT, Chadebech P, Bodivit G, Vieira-Martins P, Grunenwald A, Boudhabhay I, Poillerat V, Pakdaman S, Kiger L, Jouard A, Audureau E, Pirenne F, Galactéros F, Frémeaux-Bacchi V, Bartolucci P. Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol 2020;95:456-64. [PMID: 31990387 DOI: 10.1002/ajh.25742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
117 Patriquin CJ, Kuo KHM. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfus Med Rev 2019;33:256-65. [PMID: 31703946 DOI: 10.1016/j.tmrv.2019.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
118 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
119 van Herpt TTW, Timmermans SAMEG, van Mook WNKA, van Bussel BCT, van der Horst ICC, Maessen JG, Natour E, van Paassen P, Heuts S. Postsurgical Thrombotic Microangiopathy and Deregulated Complement. JCM 2022;11:2501. [DOI: 10.3390/jcm11092501] [Reference Citation Analysis]
120 Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12:383-401. [PMID: 27211870 DOI: 10.1038/nrneph.2016.70] [Cited by in Crossref: 248] [Cited by in F6Publishing: 246] [Article Influence: 41.3] [Reference Citation Analysis]
121 Willrich MA, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, Rivard AM, Hetrick MD, Olson RN, Bryant SC, Snyder MR, Murray DL. The impact of eculizumab on routine complement assays. Journal of Immunological Methods 2018;460:63-71. [DOI: 10.1016/j.jim.2018.06.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
122 Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 2016;51:1241-4. [PMID: 27064689 DOI: 10.1038/bmt.2016.87] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
123 Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship TH. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2016;221:715-8. [DOI: 10.1016/j.imbio.2015.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
124 Al-Mufti F, Amuluru K, Sahni R, Bekelis K, Karimi R, Ogulnick J, Cooper J, Overby P, Nuoman R, Tiwari A, Berekashvili K, Dangayach N, Liang J, Gupta G, Khandelwal P, Dominguez JF, Sursal T, Kamal H, Dakay K, Taylor B, Gulko E, El-Ghanem M, Mayer SA, Gandhi C. Cerebral Venous Thrombosis in COVID-19: A New York Metropolitan Cohort Study. AJNR Am J Neuroradiol 2021;42:1196-200. [PMID: 33888450 DOI: 10.3174/ajnr.A7134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
125 Youssef L, Miranda J, Blasco M, Paules C, Crovetto F, Palomo M, Torramade-Moix S, García-Calderó H, Tura-Ceide O, Dantas AP, Hernandez-Gea V, Herrero P, Canela N, Campistol JM, Garcia-Pagan JC, Diaz-Ricart M, Gratacos E, Crispi F. Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. Sci Rep 2021;11:3048. [PMID: 33542402 DOI: 10.1038/s41598-021-82733-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
126 Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 2017;32:297-309. [PMID: 27718086 DOI: 10.1007/s00467-016-3496-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
127 Benevolo G, Nicolosi M, Santambrogio E, Vitolo U. Current options to manage Waldenström's macroglobulinemia. Expert Rev Hematol 2017;10:637-47. [PMID: 28592170 DOI: 10.1080/17474086.2017.1339596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
128 Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. Am J Kidney Dis 2019;74:56-72. [PMID: 30851964 DOI: 10.1053/j.ajkd.2018.11.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
129 Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016;29:319-29. [PMID: 27257797 DOI: 10.1097/QCO.0000000000000279] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 18.5] [Reference Citation Analysis]
130 Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Delvasto-Nuñez L, Jongerius I, Zeerleder S. It takes two to thrombosis: Hemolysis and complement. Blood Rev 2021;:100834. [PMID: 33985796 DOI: 10.1016/j.blre.2021.100834] [Reference Citation Analysis]
132 Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017;91:1420-5. [PMID: 28187980 DOI: 10.1016/j.kint.2016.12.009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 12.6] [Reference Citation Analysis]
133 Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017;187:304-15. [PMID: 27784126 DOI: 10.1111/cei.12890] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
134 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
135 Timmermans SAMEG, van Paassen P; Limburg Renal Registry. Mother and Child Reunion in "Hypertensive" End-Stage Renal Disease: Will They Complement Each Other? Nephron 2019;142:253-7. [PMID: 30870849 DOI: 10.1159/000497779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
136 Roy N, Ohtani K, Hidaka Y, Amano Y, Matsuda Y, Mori K, Hwang I, Inoue N, Wakamiya N. Three pentraxins C-reactive protein, serum amyloid p component and pentraxin 3 mediate complement activation using Collectin CL-P1. Biochim Biophys Acta Gen Subj 2017;1861:1-14. [PMID: 27864148 DOI: 10.1016/j.bbagen.2016.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
137 Timmermans SAMEG, Wérion A, Damoiseaux JGMC, Morelle J, Reutelingsperger CP, van Paassen P. Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy. Hypertension 2020;75:422-30. [PMID: 31865800 DOI: 10.1161/HYPERTENSIONAHA.119.13714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
138 Barnum SR, Bubeck D, Schein TN. Soluble Membrane Attack Complex: Biochemistry and Immunobiology. Front Immunol 2020;11:585108. [PMID: 33240274 DOI: 10.3389/fimmu.2020.585108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
139 Devresse A, Aydin S, Le Quintrec M, Demoulin N, Stordeur P, Lambert C, Gastoldi S, Pirson Y, Jadoul M, Morelle J. Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine (Baltimore) 2016;95:e4459. [PMID: 27472742 DOI: 10.1097/MD.0000000000004459] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
140 Piras R, Iatropoulos P, Bresin E, Todeschini M, Gastoldi S, Valoti E, Alberti M, Mele C, Galbusera M, Cuccarolo P, Benigni A, Remuzzi G, Noris M. Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. Front Med (Lausanne) 2020;7:579418. [PMID: 33224962 DOI: 10.3389/fmed.2020.579418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Cassol CA, Brodsky SV, Satoskar AA, Blissett AR, Cataland S, Nadasdy T. Eculizumab deposits in vessel walls in thrombotic microangiopathy. Kidney International 2019;96:761-8. [DOI: 10.1016/j.kint.2019.05.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
142 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]
143 Kellnerová S, Chatterjee S, Bayarri-Olmos R, Justesen L, Talasz H, Posch W, Kenno S, Garred P, Orth-Höller D, Grasse M, Würzner R. Shiga Toxin 2a Binds to Complement Components C3b and C5 and Upregulates Their Gene Expression in Human Cell Lines. Toxins (Basel) 2020;13:8. [PMID: 33374102 DOI: 10.3390/toxins13010008] [Reference Citation Analysis]
144 Peffault de Latour R, Fremeaux-bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, Vieira-martins P, Roncelin S, Rodriguez-otero P, Plessier A, Sicre de Fontbrune F, Abbes S, Robin M, Socié G. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015;125:775-83. [DOI: 10.1182/blood-2014-03-560540] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 11.4] [Reference Citation Analysis]
145 Inman M, Prater G, Fatima H, Wallace E. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J. 2015;8:445-448. [PMID: 26251714 DOI: 10.1093/ckj/sfv044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
146 Ramos de Carvalho JE, Schlingemann RO, Oranje M, Bemelman FJ, van Schooneveld MJ. Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome. Int Ophthalmol 2018;38:399-407. [PMID: 28275964 DOI: 10.1007/s10792-017-0470-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
147 Silecchia V, D'Onofrio G, Valerio E, Rubin G, Vidal E, Murer L. Influenza-associated hemolytic uremic syndrome: The pathogenic role of the virus. Clin Nephrol Case Stud 2021;9:45-8. [PMID: 33884256 DOI: 10.5414/CNCS110219] [Reference Citation Analysis]
148 Saito D, Watanabe E, Ashida A, Kato H, Yoshida Y, Nangaku M, Ohtsuka Y, Miyata T, Hattori N, Oda S. Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report. Crit Care Explor 2019;1:e0008. [PMID: 32166254 DOI: 10.1097/CCE.0000000000000008] [Reference Citation Analysis]
149 Mannes M, Dopler A, Zolk O, Lang SJ, Halbgebauer R, Höchsmann B, Skerra A, Braun CK, Huber-Lang M, Schrezenmeier H, Schmidt CQ. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. Blood 2021;137:443-55. [PMID: 33507296 DOI: 10.1182/blood.2020005959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
150 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
151 Mannucci P, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thrombosis Research 2015;136:851-4. [DOI: 10.1016/j.thromres.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
152 Santiesteban-Lores LE, Amamura TA, da Silva TF, Midon LM, Carneiro MC, Isaac L, Bavia L. A double edged-sword - The Complement System during SARS-CoV-2 infection. Life Sci 2021;272:119245. [PMID: 33609539 DOI: 10.1016/j.lfs.2021.119245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
153 Sagar A, Dai W, Minot M, LeCover R, Varner JD. Reduced order modeling and analysis of the human complement system. PLoS One 2017;12:e0187373. [PMID: 29155837 DOI: 10.1371/journal.pone.0187373] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
154 Afshar-Kharghan V. COMPLEMENTing the diagnosis of aHUS. Blood 2014;124:1699-700. [PMID: 25214194 DOI: 10.1182/blood-2014-07-590356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
155 Higuero Saavedra V, González-Calle V, Sobejano E, Sebastiá J, Cabrero M, Bastida JM, Puig N, Ocio EM, Mateos MV. Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma. Hemasphere 2019;3:e192. [PMID: 31723829 DOI: 10.1097/HS9.0000000000000192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
156 Tseng MH, Tsai JD, Tsai IJ, Huang SM, Huang JL, Fan WL, Lee HJ, Wu TW, Lin SH. Whole-exome sequencing detects mutations in pediatric patients with atypical hemolytic uremic syndrome in Taiwan. Clin Chim Acta 2019;494:143-50. [PMID: 30905589 DOI: 10.1016/j.cca.2019.03.1623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
157 Cid J, Fernández J, Palomo M, Blasco M, Bailó N, Diaz-Ricart M, Lozano M. Hyperhemolytic Transfusion Reaction in Non-Hemoglobinopathy Patients and Terminal Complement Pathway Activation: Case Series and Review of the Literature. Transfus Med Rev 2020;34:172-7. [PMID: 32703665 DOI: 10.1016/j.tmrv.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Timmermans SAMEG, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P. More about complement in the antiphospholipid syndrome. Blood 2020;136:1456-9. [PMID: 32462204 DOI: 10.1182/blood.2020005171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
159 Sahutoglu T, Basturk T, Sakaci T, Koc Y, Ahbap E, Sevinc M, Kara E, Akgol C, Caglayan FB, Unsal A, Daha MR. Can eculizumab be discontinued in aHUS?: Case report and review of the literature. Medicine (Baltimore) 2016;95:e4330. [PMID: 27495036 DOI: 10.1097/MD.0000000000004330] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
160 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
161 Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT. A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab. Pediatr Nephrol 2015;30:1039-42. [PMID: 25752761 DOI: 10.1007/s00467-015-3078-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
162 Li XY, Mai YF, Huang J, Pai P. Gastrointestinal infection-related disseminated intravascular coagulation mimicking Shiga toxin-mediated hemolytic uremic syndrome - implications of classical clinical indexes in making the diagnosis: A case report and literature review. World J Clin Cases 2019; 7(13): 1660-1670 [PMID: 31367625 DOI: 10.12998/wjcc.v7.i13.1660] [Reference Citation Analysis]
163 Fakhouri F, Loirat C. Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. Seminars in Hematology 2018;55:150-8. [DOI: 10.1053/j.seminhematol.2018.04.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
164 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
165 Puissant-lubrano B, Puissochet S, Congy-jolivet N, Chauveau D, Decramer S, Garnier A, Huart A, Kamar N, Ribes D, Blancher A. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab. Clinical Immunology 2017;183:1-7. [DOI: 10.1016/j.clim.2017.06.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
166 Hyvärinen S, Jokiranta TS. Minor Role of Plasminogen in Complement Activation on Cell Surfaces. PLoS One 2015;10:e0143707. [PMID: 26637181 DOI: 10.1371/journal.pone.0143707] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
167 Yoshida Y, Kato H, Nangaku M. Atypical hemolytic uremic syndrome. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-016-0088-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
168 Thurman JM. A Patient with Hemolytic Uremic Syndrome and Kidney Failure. Clin J Am Soc Nephrol 2018;13:933-6. [PMID: 29459381 DOI: 10.2215/CJN.13191117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 108] [Article Influence: 40.4] [Reference Citation Analysis]
170 Leone VF, Imeraj A, Gastoldi S, Mele C, Liguori L, Condemi C, Ruggenenti P, Remuzzi G, Carrara C. Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19. Front Pharmacol 2022;13:842473. [DOI: 10.3389/fphar.2022.842473] [Reference Citation Analysis]
171 Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Mol Immunol 2017;89:10-21. [PMID: 28576323 DOI: 10.1016/j.molimm.2017.05.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
172 Noris M, Ruggenenti P, Remuzzi G. Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)? Am J Kidney Dis 2017;70:754-7. [PMID: 29169515 DOI: 10.1053/j.ajkd.2017.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
173 Ardissino G, Longhi S, Porcaro L, Pintarelli G, Strumbo B, Capone V, Cresseri D, Loffredo G, Tel F, Salardi S, Sgarbanti M, Martelli L, Rodrigues EM, Borsa-Ghiringhelli N, Montini G, Seia M, Cugno M, Carfagna F, Consonni D, Tedeschi S. Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality. Kidney Int Rep 2021;6:1614-21. [PMID: 34169201 DOI: 10.1016/j.ekir.2021.03.885] [Reference Citation Analysis]
174 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
175 Subías M, Tortajada A, Gastoldi S, Galbusera M, López-Perrote A, Lopez Lde J, González-Fernández FA, Villegas-Martínez A, Dominguez M, Llorca O, Noris M, Morgan BP, Rodríguez de Córdoba S. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models. J Immunol 2014;193:5567-75. [PMID: 25355917 DOI: 10.4049/jimmunol.1402013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
176 Matsuyama T, Tomimatsu T, Mimura K, Yagi K, Kawanishi Y, Kakigano A, Nakamura H, Endo M, Kimura T. Complement activation by an angiogenic imbalance leads to systemic vascular endothelial dysfunction: A new proposal for the pathophysiology of preeclampsia. J Reprod Immunol 2021;145:103322. [PMID: 33887508 DOI: 10.1016/j.jri.2021.103322] [Reference Citation Analysis]
177 Mohlin FC, Gros P, Mercier E, Gris JR, Blom AM. Analysis of C3 Gene Variants in Patients With Idiopathic Recurrent Spontaneous Pregnancy Loss. Front Immunol 2018;9:1813. [PMID: 30131807 DOI: 10.3389/fimmu.2018.01813] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
178 Zuckerman R, Asif A, Costanzo EJ, Vachharajani T. Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology. J Bras Nefrol 2018;40:77-81. [PMID: 29796581 DOI: 10.1590/2175-8239-JBN-3807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
179 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
180 Patriquin CJ, Pavenski K, Garland J, Girard L, Isenring P. Complement-Amplifying Conditions in Atypical Hemolytic Uremic Syndrome: A Canadian Case Series. Can J Kidney Health Dis 2022;9:205435812211002. [DOI: 10.1177/20543581221100288] [Reference Citation Analysis]
181 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
182 Sperati CJ, Moliterno AR. Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America 2015;29:541-59. [DOI: 10.1016/j.hoc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]